Product Opportunity Scanner
Score molecules and dosage forms on market attractiveness, competition advantage, technical fit, margin, regulatory feasibility and speed to market — the engine for Rubicon's R&D capital allocation.
A decision tool that scores drug molecules on how attractive they'd be for Rubicon to develop — balancing market size, competition, technical difficulty, margin, regulatory ease and speed into a single 0–100 score.
Click any row in the table to see that molecule's score broken into its six ingredients on the right. In the bubble chart, top-left (big market, few competitors) is the sweet spot. Higher complexity is good here — it means fewer rivals can copy it.
- Opportunity score
- — Weighted 0–100 blend of the six factors; higher = more attractive to pursue.
- Price erosion
- — How fast a generic's price falls as competitors pile in — the core risk of generics.
- Complexity
- — How hard the dosage form is to make. High complexity = a barrier that protects margins.
- Para IV
- — A patent challenge in an ANDA that can win first-mover exclusivity if successful.
Opportunity Landscape
US market size × competition · bubble = opportunity score · ringed = Rubicon-relevant
Score Breakdown — Paliperidone Palmitate
Weighted 0-100 opportunity score
Molecule Opportunity Table
Click a row to view its score breakdown
| Molecule | Therapy | US mkt | Comp. | Complexity | Erosion | Opportunity score |
|---|---|---|---|---|---|---|
Paliperidone Palmitate Invega Sustenna · Depot injection (LAI) | CNS / Schizophrenia | $1.7B | 0 | 10/10 | 5% | 81 |
Liraglutide Victoza / Saxenda · Pre-filled pen (injectable) | Diabetes / Obesity (GLP-1) | $2.6B | 2 | 10/10 | 20% | 79 |
Fluticasone/Salmeterol Advair Diskus · Dry powder inhaler | Respiratory | $1.9B | 3 | 10/10 | 35% | 72 |
Lisdexamfetamine Dimesylate Vyvanse · Capsule | CNS / ADHD | $3.1B | 9 | 7/10 | 55% | 61 |
Tacrolimus Astagraf XL / Envarsus · IR capsule | Immunosuppressant | $650M | 2 | 9/10 | 25% | 61 |
Naloxone HCl Narcan · Nasal spray | Emergency / Opioid reversal | $560M | 3 | 9/10 | 30% | 57 |
Rivastigmine Exelon Patch · Transdermal patch | CNS / Alzheimer's | $420M | 4 | 9/10 | 40% | 57 |
Icosapent Ethyl Vascepa · Soft-gel capsule | Cardio-metabolic | $1.4B | 5 | 7/10 | 40% | 56 |
Dexmethylphenidate HCl Focalin XR · ER capsule | CNS / ADHD | $720M | 4 | 8/10 | 50% | 56 |
Budesonide Entocort / Uceris · DR/ER capsule | Gastrointestinal / Respiratory | $380M | 5 | 8/10 | 45% | 52 |